Mouse Anti-G6PD (AA 35-506) Recombinant Antibody (CBFYH-0209) (CBMAB-H0442-FY)
Compare
Online Inquiry
Basic Information
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
Cholesterol biosynthetic process Source: BHF-UCL
Erythrocyte maturation Source: BHF-UCL
Glucose 6-phosphate metabolic process Source: UniProtKB
Glucose metabolic process Source: UniProtKB-KW
Glutathione metabolic process Source: BHF-UCL
Lipid metabolic process Source: BHF-UCL
NADPH regeneration Source: BHF-UCL
NADP metabolic process Source: UniProtKB
Negative regulation of cell growth involved in cardiac muscle cell development Source: Ensembl
Negative regulation of protein glutathionylation Source: BHF-UCL
Negative regulation of reactive oxygen species metabolic process Source: Ensembl
Pentose biosynthetic process Source: BHF-UCL
Pentose-phosphate shunt Source: BHF-UCL
Pentose-phosphate shunt, oxidative branch Source: BHF-UCL
Positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel Source: Ensembl
Regulation of neuron apoptotic process Source: Ensembl
Response to ethanol Source: Ensembl
Response to food Source: Ensembl
Response to iron(III) ion Source: Ensembl
Response to organic cyclic compound Source: Ensembl
Ribose phosphate biosynthetic process Source: BHF-UCL
Substantia nigra development Source: UniProtKB
The disease is caused by variants affecting the gene represented in this entry. Deficiency of G6PD is associated with hemolytic anemia in two different situations. First, in areas in which malaria has been endemic, G6PD-deficiency alleles have reached high frequencies (1% to 50%) and deficient individuals, though essentially asymptomatic in the steady state, have a high risk of acute hemolytic attacks. Secondly, sporadic cases of G6PD deficiency occur at a very low frequencies, and they usually present a more severe phenotype. Several types of NSHA are recognized. Class-I variants are associated with severe NSHA; class-II have an activity <10% of normal; class-III have an activity of 10% to 60% of normal; class-IV have near normal activity. A disease characterized by G6PD deficiency, acute hemolytic anemia, fatigue, back pain, and jaundice. In most patients, the disease is triggered by an exogenous agent, such as some drugs, food, or infection. Increased unconjugated bilirubin, lactate dehydrogenase, and reticulocytosis are markers of the disorder. Although G6PD deficiency can be life-threatening, most patients are asymptomatic throughout their life.
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon
$30 eGift Card
Submit a review
Loading...
Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols
Related Products
Mouse Anti-G6PD Recombinant Antibody (CBLG1-414) (CAT#: CBMAB-G1573-LY)
Mouse Anti-G6PD Recombinant Antibody (2A7B12) (CAT#: CBMAB-AP2426LY)
Mouse Anti-G6PD Recombinant Antibody (CBLG1-409) (CAT#: CBMAB-G1568-LY)
Mouse Anti-G6PD Recombinant Antibody (CBLG1-412) (CAT#: CBMAB-G1571-LY)
Mouse Anti-G6PD Recombinant Antibody (CBFYH-0210) (CAT#: CBMAB-H0448-FY)
Mouse Anti-G6PD (AA 35-506) Recombinant Antibody (AT2F6) (CAT#: CBMAB-H1082-FY)
Mouse Anti-G6PD Recombinant Antibody (CBT576) (CAT#: V2LY-0625-LY3412)
Mouse Anti-G6PD Recombinant Antibody (2F6) (CAT#: CBMAB-G0103-LY)
Mouse Anti-G6PD Recombinant Antibody (CBLG1-405) (CAT#: CBMAB-G1564-LY)
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
